PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (PAMELA)

Clinical Trial ID NCT01973660

PubWeight™ 0.75^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01973660

Top papers